Key result
DOACs show no significant benefit over VKA for thromboembolism in AF with bioprosthetic valves.
Why the study?
Although direct oral anticoagulants (DOACs) are contraindicated in patients with mechanical valves, data on their efficacy and safety compared with vitamin K antagonists in patients with atrial fibrillation (AF) and bioprosthetic valves remain limited.
Do direct oral anticoagulants reduce the risk of all-cause stroke or systemic embolic events compared to vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valve repair or replacement?
Meta-Analysis (n=5,333)
Do direct oral anticoagulants reduce the risk of all-cause stroke or systemic embolic events compared to vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valve repair or replacement?
In patients with atrial fibrillation and bioprosthetic valves, DOACs show similar efficacy and safety to VKAs regarding stroke/systemic embolism, major bleeding, and all-cause mortality, supporting their use as a viable alternative.
Answers are grounded in this paper and cite their sources.
May support DOAC preference over VKA in AF with bioprosthetic valves; extends limited evidence but leaves open need for dedicated RCTs.
Background Use of direct oral anticoagulants (DOACs) is contraindicated in patients with mechanical valves. However data on their use in patients with atrial fibrillation (AF) and bioprosthetic valves (BV) is still limited. Purpose To assess the safety and efficacy of DOACs versus Vitamin K antagonist (VKA) in patients with AF after BV repair or replacement. Methods We performed a comprehensive review of electronic databases (PubMed, Embase, Scopus, Cochrane) using MeSH terms and keywords for DOACs, AF and BVs from inception through December 2021. Randomized clinical trials (RCT) or observational studies that reported clinical outcomes comparing DOACs versus VKA in patients with AF and BVs were eligible for inclusion. Ten articles were reviewed for full text. Primary outcome was a composite of all cause stroke or systemic embolic event. Secondary outcomes included major bleeding and all-cause mortality. Subgroup analysis stratified by study design was performed. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using Mantel-Haenszel method with DerSimonian-Laird estimator for tau2 for random effects model. Interstudy heterogeneity was assessed using the Higgins I 2 value. All statistical analysis was performed using RevMan 5.4.1 software. Results Ten studies (5 RCTs, 5 observational studies) with a total of 5,333 patients (DOACs n=2434; VKA n=2899) were included. Aortic, mitral and mixed BV repair or replacement were 74.2%, 25.6% and 0.02% respectively. The mean age was 72.6±11.9 years. The mean follow-up was 15.7±12.9 months. Type of DOACs included apixaban (n=553, 22.7%), rivaroxaban (n=893, 36.7%), dabigatran (n=151, 6.2%) and edoxaban (n=837, 34.4%). There was no significant difference in primary outcome of stroke or systemic embolic event (RR: 0.79; CI: 0.56–1.11; p>0.05; I2=12%) or secondary outcomes of major bleeding (RR: 0.84; CI: 0.64–1.11; p>0.05; I2=45%), and all-cause mortality (RR: 0.84; CI: 0.64–1.11; p>0.05; I2=29%) between DOACs compared with VKA. Conclusion In patients with AF and BV, DOACs are non-inferior to VKA for risk of stroke or systemic embolism, major bleeding, and all-cause mortality. Thus, DOACs can serve as a viable alternative to VKAs which have a narrow therapeutic index, multiple drug interactions, and require frequent monitoring.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2022) conducted a meta-analysis in Concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement (n=5,333). Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) vs. Vitamin K antagonist (VKA) was evaluated on Composite of all-cause stroke or systemic embolic event (RR 0.79, 95% CI 0.56-1.11, p=>0.05). Direct oral anticoagulants showed no significant difference compared to VKA for stroke or systemic embolic events in AF with bioprosthetic valves.
Synapse has enriched 10 related papers. Consider them for comparative context: